Zevra Therapeutics, Inc. Cost of Revenue
Zevra Therapeutics, Inc. (ZVRA) reported Cost of Revenue of $2.94 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-01.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2024-04-01
- Zevra Therapeutics, Inc. cost of revenue for the quarter ending 2023-12-31 was $2.00M, a 8986.36% increase year-over-year.
- Zevra Therapeutics, Inc. cost of revenue for the quarter ending 2023-09-30 was $144.00K, a 2.13% increase year-over-year.
- Zevra Therapeutics, Inc. cost of revenue for the quarter ending 2023-06-30 was $677.00K, a 1227.45% increase year-over-year.
- Zevra Therapeutics, Inc. cost of revenue for the quarter ending 2023-03-31 was $125.00K, a 1462.50% increase year-over-year.
- Zevra Therapeutics, Inc. cost of revenue for fiscal 2023 was $2.94M, a 1226.58% increase from fiscal 2022.
- Zevra Therapeutics, Inc. cost of revenue for fiscal 2022 was $222.00K, a 89.22% decline from fiscal 2021.
- Zevra Therapeutics, Inc. cost of revenue for fiscal 2021 was $2.06M.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month | Cost of Revenue 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $2.14M derived: sum of 2 quarters · filed 2024-04-01 | $2.82M derived: sum of 3 quarters · filed 2024-04-01 | $2.94M 10-K · filed 2024-04-01 | |
| 2023-09-30 | $144.00K 10-Q · filed 2023-11-07 | $821.00K derived: sum of 2 quarters · filed 2023-11-07 | $946.00K 10-Q · filed 2023-11-07 | $968.00K derived: sum of 4 quarters · filed 2024-04-01 | |
| 2023-06-30 | $677.00K 10-Q · filed 2023-08-14 | $802.00K 10-Q · filed 2023-08-14 | $824.00K derived: sum of 3 quarters · filed 2024-04-01 | $965.00K derived: sum of 4 quarters · filed 2024-04-01 | |
| 2023-03-31 | $125.00K 10-Q · filed 2023-05-15 | $147.00K derived: sum of 2 quarters · filed 2024-04-01 | $288.00K derived: sum of 3 quarters · filed 2024-04-01 | $339.00K derived: sum of 4 quarters · filed 2024-04-01 | |
| 2022-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $163.00K derived: sum of 2 quarters · filed 2024-04-01 | $214.00K derived: sum of 3 quarters · filed 2024-04-01 | $222.00K 10-K · filed 2024-04-01 | $343.00K 10-K · filed 2023-03-07 |
| 2022-09-30 | $141.00K 10-Q · filed 2023-11-07 | $192.00K derived: sum of 2 quarters · filed 2023-11-07 | $200.00K 10-Q · filed 2023-11-07 | $259.00K derived: sum of 4 quarters · filed 2023-11-07 | |
| 2022-06-30 | $51.00K 10-Q · filed 2023-08-14 | $59.00K 10-Q · filed 2023-08-14 | $118.00K derived: sum of 3 quarters · filed 2023-08-14 | $118.00K derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $8.00K 10-Q · filed 2023-05-15 | $67.00K derived: sum of 2 quarters · filed 2023-05-15 | $67.00K derived: sum of 3 quarters · filed 2023-05-15 | $1.07M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | $59.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $59.00K derived: sum of 2 quarters · filed 2023-03-07 | $1.06M derived: sum of 3 quarters · filed 2023-03-07 | $2.06M 10-K · filed 2023-03-07 | |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-10 | $1.00M derived: sum of 2 quarters · filed 2022-11-10 | $2.00M 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $1.00M 10-Q · filed 2022-08-12 | $2.00M 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |